IL159210A0 - Mutant forms of cholera holotoxin as an adjuvant - Google Patents
Mutant forms of cholera holotoxin as an adjuvantInfo
- Publication number
- IL159210A0 IL159210A0 IL15921002A IL15921002A IL159210A0 IL 159210 A0 IL159210 A0 IL 159210A0 IL 15921002 A IL15921002 A IL 15921002A IL 15921002 A IL15921002 A IL 15921002A IL 159210 A0 IL159210 A0 IL 159210A0
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- cholera
- adjuvant
- mutant forms
- cholera holotoxin
- Prior art date
Links
- 206010008631 Cholera Diseases 0.000 title abstract 4
- 229930186900 holotoxin Natural products 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 102000009016 Cholera Toxin Human genes 0.000 abstract 1
- 108010049048 Cholera Toxin Proteins 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29653701P | 2001-06-07 | 2001-06-07 | |
PCT/US2002/020978 WO2002098368A2 (en) | 2001-06-07 | 2002-06-05 | Mutant forms of cholera holotoxin as an adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159210A0 true IL159210A0 (en) | 2004-06-01 |
Family
ID=23142433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15921002A IL159210A0 (en) | 2001-06-07 | 2002-06-05 | Mutant forms of cholera holotoxin as an adjuvant |
IL159210A IL159210A (en) | 2001-06-07 | 2003-12-04 | Mutant forms of cholera holotoxin as an adjuvant |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL159210A IL159210A (en) | 2001-06-07 | 2003-12-04 | Mutant forms of cholera holotoxin as an adjuvant |
Country Status (13)
Country | Link |
---|---|
US (3) | US7285281B2 (es) |
EP (1) | EP1404368B1 (es) |
JP (2) | JP2004535187A (es) |
KR (1) | KR100898648B1 (es) |
CN (2) | CN1297316C (es) |
AT (1) | ATE451386T1 (es) |
AU (1) | AU2002346249B2 (es) |
BR (1) | BR0210225A (es) |
CA (1) | CA2449663A1 (es) |
DE (1) | DE60234695D1 (es) |
IL (2) | IL159210A0 (es) |
MX (1) | MXPA03011133A (es) |
WO (1) | WO2002098368A2 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
US7384640B1 (en) * | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
EP2329846B1 (en) * | 2000-09-08 | 2014-11-12 | University Of Maryland, Baltimore | Genetically engineered co-expression DNA vaccines, construction methods and uses thereof |
KR100877258B1 (ko) * | 2001-06-07 | 2009-01-12 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
JP2004535187A (ja) * | 2001-06-07 | 2004-11-25 | ワイス・ホールデイングス・コーポレーシヨン | アジュバントとしてのコレラホロトキシンの突然変異形 |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
CN100450551C (zh) * | 2002-11-29 | 2009-01-14 | 中国医学科学院基础医学研究所 | 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途 |
EP1603950A2 (en) * | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
MY144231A (en) | 2003-12-17 | 2011-08-15 | Wyeth Corp | Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
EA012984B1 (ru) | 2003-12-17 | 2010-02-26 | Вайет | Конъюгаты иммуногенных пептидных носителей и способы их получения |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
MXPA06013448A (es) | 2004-05-21 | 2007-01-23 | Wyeth Corp | Proteina alterada que liga a la fibronectina en staphylococcus aureus. |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
BRPI0516974A (pt) | 2004-10-21 | 2008-09-30 | Wyeth Corp | composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis |
IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
PT2495307T (pt) | 2006-07-13 | 2018-05-10 | Wyeth Llc | Produção do fator ix de coagulação com padrão melhorado de glicosilação |
JP5401319B2 (ja) | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US9012180B2 (en) | 2007-03-02 | 2015-04-21 | Wyeth Llc | Use of copper and glutamate in cell culture for production of polypeptides |
CL2007002710A1 (es) * | 2007-09-20 | 2008-01-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. |
EP2303318A2 (en) | 2008-06-20 | 2011-04-06 | Wyeth LLC | Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains |
CA2736799A1 (en) | 2008-08-25 | 2010-03-11 | Burnham Institute For Medical Research | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
EP2346529B1 (en) | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
NZ597191A (en) | 2009-06-22 | 2013-11-29 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
BRPI1015567A2 (pt) | 2009-06-22 | 2021-08-31 | Wyeth Llc | Composições imunogênicas de antígenos de staphylococcus aureus |
EP2575870B1 (en) | 2010-06-04 | 2016-12-07 | Wyeth LLC | Vaccine formulations |
EP3246044B2 (en) | 2010-08-23 | 2024-04-10 | Wyeth LLC | Stable formulations of neisseria meningitidis rlp2086 antigens |
ES2864635T3 (es) | 2010-09-10 | 2021-10-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
AU2011346535B2 (en) | 2010-12-22 | 2015-09-24 | Wyeth Llc | Stable immunogenic compositions of Staphylococcus aureus antigens |
AU2012225146A1 (en) * | 2011-03-09 | 2013-09-26 | Ondek Pty Ltd | Gene expression and eradication system in Helicobacter pylori |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CA2879443A1 (en) | 2012-07-19 | 2014-01-23 | Zoetis Llc | Bovine influenza virus compositions |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
MX363511B (es) | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
EP4169929A1 (en) | 2012-12-20 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions comprising pn-serotype 12f |
ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
AU2014234982A1 (en) | 2013-03-15 | 2015-09-24 | Zoetis Services Llc | Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine |
WO2015033251A2 (en) | 2013-09-08 | 2015-03-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
EP3957321A3 (en) | 2014-01-21 | 2022-07-13 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
HUE055553T2 (hu) | 2014-01-21 | 2021-12-28 | Pfizer | Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
CA2939416A1 (en) | 2014-02-14 | 2015-08-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
CN106535930A (zh) | 2014-03-11 | 2017-03-22 | 明尼苏达大学董事会 | 猪流行性腹泻病毒疫苗及其使用方法 |
KR20190049940A (ko) | 2015-02-19 | 2019-05-09 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
PE20180172A1 (es) | 2015-05-04 | 2018-01-22 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos |
CA2995101A1 (en) | 2015-08-14 | 2017-02-23 | Zoetis Services Llc | Mycoplasma bovis compositions |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
WO2017220753A1 (en) | 2016-06-22 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
EP3641828B1 (en) | 2017-06-23 | 2023-11-22 | Affinivax, Inc. | Immunogenic compositions |
US20210085775A1 (en) * | 2017-12-15 | 2021-03-25 | Valneva Sweden Ab | Methods and composition for preventing and/or treating cancer |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
EP4003410A1 (en) | 2019-07-31 | 2022-06-01 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
EP4136219A1 (en) | 2020-04-16 | 2023-02-22 | Par'Immune SAS | 28 kda gst proteins from schistosoma for the treatment of vasculitis |
EP4136095A1 (en) | 2020-04-17 | 2023-02-22 | Regents of the University of Minnesota | Sars-cov-2 spike receptor binding domain and compositions and methods thereof |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
IL301402A (en) | 2020-09-17 | 2023-05-01 | Inst Nat Sante Rech Med | An immunogenic product containing a segment of ige for the treatment of inflammatory disorders mediated by ige |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
CN117187301B (zh) * | 2023-09-06 | 2024-08-20 | 迪福润丝(合肥)生物科技有限公司 | 一种含黏膜佐剂相关基因的重组ndv载体及相应的疫苗株和疫苗 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US4883761A (en) | 1986-03-25 | 1989-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
US5925546A (en) | 1987-11-02 | 1999-07-20 | Chiron S.P.A. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
KR100188323B1 (ko) | 1989-03-09 | 1999-06-01 | 이곤 이이 버어그 | 비타입성 헤모필루스 인플렌자에 대한 백신 |
US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
US5709879A (en) | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
GB9202219D0 (en) | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
US6290962B1 (en) | 1992-11-03 | 2001-09-18 | Oravax, Inc. | Urease-based vaccine and treatment for helicobacter infection |
US5972336A (en) | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
AU683236B2 (en) | 1993-03-15 | 1997-11-06 | American Cyanamid Company | Expression of pertussis holotoxin in Bordetella pertussis |
DE4322211A1 (de) * | 1993-07-03 | 1995-01-12 | Basf Ag | Wäßrige, mehrphasige, stabile Fertigformulierung für Pflanzenschutz-Wirkstoffe und Verfahren zu ihrer Herstellung |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
US6245337B1 (en) | 1994-08-25 | 2001-06-12 | Washington University | Haemophilus adherence and penetration proteins |
US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
WO1997005267A2 (en) | 1995-07-26 | 1997-02-13 | Maxim Pharmaceuticals | Mucosal delivery of polynucleotides |
US5965354A (en) | 1995-07-28 | 1999-10-12 | Chiron Corporation | Herpes simplex virus diagnostics |
US6395964B1 (en) | 1995-10-24 | 2002-05-28 | The Texas A&M University System | Oral immunization with transgenic plants |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
US6685949B1 (en) | 1998-01-13 | 2004-02-03 | The United States Of America As Represented By The Department Of Health & Human Services | Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans |
US6558677B2 (en) | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
WO1998032461A1 (en) | 1997-01-29 | 1998-07-30 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic adjuvant for hiv |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
WO1998045324A1 (en) * | 1997-04-04 | 1998-10-15 | The Uab Research Foundation | Use of cholera toxin mutants as mucosal adjuvants |
IS4518A (is) | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20060121051A1 (en) * | 1998-02-19 | 2006-06-08 | Kenten John H | Heat shock fusion-based vaccine system |
AU770333B2 (en) | 1998-09-30 | 2004-02-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Mutant cholera holotoxin as an adjuvant |
BR9916515A (pt) * | 1998-12-22 | 2001-11-06 | Thompson Boyce Plant Res | Polinucleotìdeo, vetor de expressão, células de e. coli e de agrobacterium tumefaciens transformadas com o vetor de expressão, célula de planta transgênica, semente de planta transgênica, célula eucariótica transgênica, composição imunogênica, método de evocar uma resposta imune em um animal ou ser humano, planta transgênica, e, adjuvante |
EP1034792A1 (en) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
AU2001271268A1 (en) | 2000-05-19 | 2001-12-03 | The Administrators Of The Tulane Educational Fund | Hybrid lt-a/ct-b holotoxin for use as an adjuvant |
GB0108024D0 (en) * | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
KR100877258B1 (ko) | 2001-06-07 | 2009-01-12 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
JP2004535187A (ja) * | 2001-06-07 | 2004-11-25 | ワイス・ホールデイングス・コーポレーシヨン | アジュバントとしてのコレラホロトキシンの突然変異形 |
GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
ATE458496T1 (de) * | 2002-01-14 | 2010-03-15 | Novartis Vaccines & Diagnostic | Hiv-vakzine und anwendungsverfahren |
US20060069052A1 (en) | 2003-02-14 | 2006-03-30 | David Hone | DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity |
EP1603950A2 (en) * | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
-
2002
- 2002-06-05 JP JP2003501410A patent/JP2004535187A/ja not_active Withdrawn
- 2002-06-05 DE DE60234695T patent/DE60234695D1/de not_active Expired - Fee Related
- 2002-06-05 CN CNB028154126A patent/CN1297316C/zh not_active Expired - Fee Related
- 2002-06-05 WO PCT/US2002/020978 patent/WO2002098368A2/en active Application Filing
- 2002-06-05 MX MXPA03011133A patent/MXPA03011133A/es not_active Application Discontinuation
- 2002-06-05 BR BR0210225-0A patent/BR0210225A/pt not_active IP Right Cessation
- 2002-06-05 AU AU2002346249A patent/AU2002346249B2/en not_active Ceased
- 2002-06-05 AT AT02752145T patent/ATE451386T1/de not_active IP Right Cessation
- 2002-06-05 CA CA002449663A patent/CA2449663A1/en not_active Abandoned
- 2002-06-05 KR KR1020037015999A patent/KR100898648B1/ko not_active IP Right Cessation
- 2002-06-05 CN CNA2006101684314A patent/CN1977971A/zh active Pending
- 2002-06-05 IL IL15921002A patent/IL159210A0/xx unknown
- 2002-06-05 US US10/478,307 patent/US7285281B2/en not_active Expired - Fee Related
- 2002-06-05 EP EP02752145A patent/EP1404368B1/en not_active Expired - Lifetime
-
2003
- 2003-12-04 IL IL159210A patent/IL159210A/en not_active IP Right Cessation
-
2006
- 2006-12-15 US US11/639,810 patent/US7361355B2/en not_active Expired - Fee Related
-
2007
- 2007-10-22 US US11/876,418 patent/US20080213303A1/en not_active Abandoned
-
2009
- 2009-09-18 JP JP2009217704A patent/JP2010017190A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20040073965A (ko) | 2004-08-21 |
US20070116715A1 (en) | 2007-05-24 |
EP1404368A4 (en) | 2006-05-17 |
EP1404368A2 (en) | 2004-04-07 |
ATE451386T1 (de) | 2009-12-15 |
CN1977971A (zh) | 2007-06-13 |
WO2002098368A2 (en) | 2002-12-12 |
MXPA03011133A (es) | 2004-12-06 |
WO2002098368A3 (en) | 2003-05-08 |
JP2004535187A (ja) | 2004-11-25 |
JP2010017190A (ja) | 2010-01-28 |
US20080213303A1 (en) | 2008-09-04 |
CN1297316C (zh) | 2007-01-31 |
US20040181036A1 (en) | 2004-09-16 |
EP1404368B1 (en) | 2009-12-09 |
CN1538854A (zh) | 2004-10-20 |
US7361355B2 (en) | 2008-04-22 |
AU2002346249B2 (en) | 2007-03-15 |
US7285281B2 (en) | 2007-10-23 |
DE60234695D1 (de) | 2010-01-21 |
CA2449663A1 (en) | 2002-12-12 |
KR100898648B1 (ko) | 2009-05-22 |
IL159210A (en) | 2010-04-29 |
BR0210225A (pt) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159210A0 (en) | Mutant forms of cholera holotoxin as an adjuvant | |
MXPA03011135A (es) | Formas mutantes de holotoxina de colera como adyuvante. | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
IL142231A0 (en) | Mutant cholera holotoxin as an adjuvant | |
WO2002009746A3 (en) | Vaccines comprising outer membrane vesciles from gram negative bacteria | |
EP1955709A3 (en) | Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines | |
WO2004030608A3 (en) | Nanoemulsion vaccines | |
DE122010000042I1 (de) | Solubilisierung von capsulären Polysacchariden | |
NO20031646L (no) | Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
AU5162201A (en) | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 | |
PL351894A1 (en) | Novel compositions | |
EP1467771A4 (en) | MYCOBACTERIAL VACCINE | |
CY1110327T1 (el) | DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ | |
WO2002075507A3 (en) | Anti-bacterial vaccine compositions | |
WO2001078787A3 (en) | Lipopolysaccharide-conjugate vaccine for sepsis treatment | |
WO2006095176A3 (en) | Vaccine formulation | |
HK1138516A1 (en) | Parenteral vaccine formulations and uses thereof | |
MY127452A (en) | Vaccines. | |
AU6761301A (en) | Adjuvant composition comprising fha protein or fragment of fha protein in free form |